Co-Diagnostics
CODX
43 hedge funds and large institutions have $4.93M invested in Co-Diagnostics in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 16 reducing their positions, and 12 closing their positions.
245% more call options, than puts
Call options by funds: $162K | Put options by funds: $47K
0.09% less ownership
Funds ownership: 0.58% → 0.49% (-0.09%)
16% less funds holding
Funds holding: 51 → 43 (-8)
39% less capital invested
Capital invested by funds: $8.06M → $4.93M (-$3.13M)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
56% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
+$94.5K |
| 2 |
KOC
Koss-Olinger Consulting
Gainesville,
Florida
|
+$42.8K |
| 3 |
KAS
Kestra Advisory Services
Austin,
Texas
|
+$34.4K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$28.4K |
| 5 |
Renaissance Technologies
New York
|
+$6.89K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$628K |
| 2 |
American Century Companies
Kansas City,
Missouri
|
-$268K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$93.1K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$81K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$72.9K |
CODX Hedge Fund Activity: Q2 2023 in Review
43 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q2 2023, worth a combined $4.93M — down 39% from $8.06M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CODX and 6 opened new positions — a net loss of 6 holders — while 16 trimmed existing stakes and 7 added.
The largest buyer was Man Group, opening a new position worth an estimated $94.5K. The largest seller was Morgan Stanley, cutting an estimated $628K.
- 43 institutional investors held Co-Diagnostics (CODX) as of Q2 2023, down from 51 in Q1 2023.
- Funds reported $4.93M of Co-Diagnostics stock for Q2 2023, down 39% quarter-over-quarter.
- 6 funds opened new Co-Diagnostics positions in Q2 2023 and 12 closed out, a net change of -6 holders.
- The largest Co-Diagnostics buyer in Q2 2023 was Man Group, an estimated $94.5K added.
- The largest Co-Diagnostics seller in Q2 2023 was Morgan Stanley, an estimated $628K sold.
Based on aggregated 13F filings for Q2 2023.